Abstract: Disclosed herein is a recombinant polypeptide comprising 1 to 20 copies of an IL-17RB inactivation site (IRIS) sequence. Also disclosed herein is the use of the recombinant polypeptide in the preparation of a conjugate for the treatment of cancers.

Abstract: An antimicrobial peptide, the peptide comprising 2 to 20 variable domains, each variable domain is a sequence of 2 to 20 consecutive basic amino acids, wherein (a) the variable domains are separated from each other by a variable linker, (b) the variable linker can have 1 to 20 any amino acids other than two or more consecutive basic amino acids, and (c) the peptide has no more than 100 amino acids.

Abstract: Immunogenic compositions comprising hemagglutinin (HA) variants and/or neuraminidase (NA) variants, which may be contained in an influenza A virus, and uses thereof for eliciting immune responses against influenza A virus.

Abstract: The present invention is directed to methods of treating hypertriglyceridemia or hypertriglyceridemia-related diseases in a subject by using recombinant PRAP1 polypeptides. According to some embodiments of the present disclosure, the subject is a human, in which the recombinant PRAP1 polypeptide comprises the amino acid sequence 100% identical to SEQ ID NO: 1 or 2. According to certain embodiments of the present disclosure, the subject is a mouse, in which the recombinant PRAP1 polypeptide comprises the amino acid sequence 100% identical to SEQ ID NO: 3 or 4.

Abstract: The present invention relates to a method for treating autism spectrum disorders (ASD) or ASD-like symptom, particularly by administering a zinc ion source and/or a serine component e.g. D-serine or its precursor/analogue, optionally in combination with a mixture of branched-chain amino acids (BCAAs). The present invention also relates to a combination, kit or composition for performing the method for treatment as described herein. Further described is use of a zinc ion source and/or a serine component and optional BCAAs for manufacturing a medicament for treating a symptom or disease characteristics associated with ASD or ASD-associated disorder or as a food supplement for ameliorating relevant symptoms in a subject in need thereof. The present invention further provides an animal model for autistic spectrum disorder (ASD) with deficient CTTNBP2 gene, and a method for identifying an ingredient effective in the treatment of ASD by using such animal model.

Abstract: Disclosed herein is an integrated microfluidic chip for detecting cancerous cells, particularly, cholangio-cancerous cells, from a biological sample. Also disclosed herein is a method of detecting cholangio-cancerous cells from a biological sample.

Abstract: Disclosed herein are novel polyhydroxylated indolizidine and pyrrolizidine derivates and methods for using the same in the treatment of cancer. The present polyhydroxylated indolizidine and pyrrolizidine derivates has the structure of formula (I), wherein: X is O or b and c are independently an integral of 0 or and 1; R is selected from the group consisting of H, C1-6 alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, aralkyl, aralkenyl, aralkynyl, heteroaralkyl, heteroaralkenyl, beteroaralkynyl, heterocyclyl, alkoxy, aryloxy, and sulfonyl.

Abstract: The present invention provides a lectin from Crenomytilus grayanus or Mytilus trossulus as diagnostic reagents for IgA nephropathy. The present invention also provides a diagnostic kit for detecting Galactose-deficient IgA1 (Gd-IgA1), comprising RussiaSea-001 (also called as CGL) isolated from Crenomytilus grayanus or RussiaSea-002 (also called as MTL) isolated from Mytilus trossulus. The present invention further provides a method for detecting Gd-IgA1 using RussiaSea-001 or RussiaSea-002.

Abstract: The present invention relates to antibodies that bind to ENO1 and applications thereof. The applications encompass therapies and diagnostics of diseases or disorders associated with ENO1 activation and progression thereof using such antibodies. Specifically, the antibodies of the present invention bind to ENO1 on the surface of cancer cells and are useful in reducing cancer cell growth and metastasis and prolonging survival time. The antibodies of the present invention may also be used in detecting ENO1, diagnosis and prognosis of cancer and monitoring cancer progression. The present invention also provides a method for screening for a candidate agent for cancer therapy.

Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).

Abstract: Disclosed herein is a nanocomposite comprising a core-shell nanoparticle and a core-shell quantum dot. The core-shell nanoparticle comprises a phosphor core, a shell layer, and a cleavable peptide. The core-shell quantum dot comprises a center core, an intermediate layer, an outer layer, a silica layer, and an arginylglycylaspartic acid (RGD) peptide. The core-shell nanoparticle and the core-shell quantum dot are linked to each other via forming a peptide bond between the cleavable peptide and the RGD peptide. Also disclosed are the uses of the nanocomposite in making a diagnosis of tumors.

Abstract: A spin-orbit torque device is disclosed, which includes: a magnetic layer; and a non-magnetic layer adjacent to the magnetic layer and comprising a spin-Hall material, wherein the spin-Hall material comprises NixCu1-x alloy, and x is in a range from 0.4 to 0.8.

Abstract: The present invention relates to an antagonist of interleukin-17B receptor (IL-17RB) which features interruption of the interaction of IL-17RB and MLK4. The present invention also relates to use of such antagonist for treatment of diseases or disorders associated with IL-17RB activation. Further disclosed is a phosphorylated IL-17RB as a biomarker for predicting prognosis and/or monitoring progression of cancer.

Abstract: A surface coating comprising a hydrophilic polymer and polyelectrolyte multilayers. Also, a cell culture system including a cell culture article having a surface coated with the surface coating. Also, methods of preparing the surface coatings and systems.

Abstract: Disclosed herein is a method for identifying and treating an early-stage hepatocellular carcinoma (HCC) in a subject. The method mainly includes determining the level of serum amyloid A (SAA) protein, and providing anti-cancer treatment based on the determined level of SAA protein. According to some embodiments of the present disclosure, the anti-cancer treatment is provided when the determined level of SAA protein is lower than that of a first control sample, or when the determined level of SAA protein is higher than that of a second control sample. In some embodiments, the first control sample is derived from a subject having a late stage HCC, and the second control sample is derived from a subject having a liver disease that is any of hepatitis, liver cirrhosis, or a combination thereof.

Abstract: A method for manufacturing a polymer-based fibrous scaffold is disclosed. The method includes the following step: providing an electrospinning device comprising a collector; and injecting a polymer solution into the electrospinning device to produce a single jet fiber, wherein the single jet fiber is piled on the collector to form a fibrous scaffold.

Abstract: The present disclosure relates to fungi, a culture filtrate thereof and a polysaccharide and their applications in inducing or priming plant resistance to viruses. Aspects of the present disclosure provides a cultured filtrate, derived from a fungus belonging to the genus Trichosporon, induces strong resistance to various viruses on different plants.

Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).

Abstract: The present disclosure provides compounds of Formulas (I), (II), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating proliferative diseases, for example, cancer (e.g., lung cancer), and infectious diseases (e.g., bacterial infections).

Abstract: Disclosed is a modified carbonaceous material, which includes hexagonal carbon networks in a layered stacking structure and acidic functional groups bonded to the hexagonal carbon networks and mainly existing at edges of the layered carbonaceous structure. Accordingly, the close proximity of acid moiety at the edges can resemble the center of hydrolysis enzymes, resulting in enhancement of hydrolytic efficiency. Additionally, the acid-functionalized carbonaceous material can also be applied in the capture and storage of carbon dioxide due to its unexpectedly higher capacity for CO2 molecular.